Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06991101 · ClinicalTrials.gov registry record · Phase 2
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
A Phase 2 study of Glioblastoma and Glioblastoma Multiforme, sponsored by Baptist Health South Florida.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 190
- Enrollment target
- 1
- Study location
NCT06991101 is a Phase 2 study of Glioblastoma and Glioblastoma Multiforme that is actively recruiting participants, run by Baptist Health South Florida. The registered enrollment target is 190 participants, above the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target (76% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06991101, a Phase 2 study of Glioblastoma and Glioblastoma Multiforme, is actively recruiting participants, sponsored by Baptist Health South Florida.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 190 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to test the safety and effectiveness of the investigational drug ruxolitinib when it is combined with standard of care treatment (radiation therapy and temozolomide) for the treatment of newly diagnosed glioblastoma. Half the people in the study will be assigned to take the study drug ruxolitinib in addition to the standard of care temozolomide and radiation therapy and the other half will be assigned to the standard of care temozolomide and radiation therapy only. This assignment will be randomized in a 1-to-1 ratio, like the flip of a coin.
Conditions Studied
Interventions
- RADIATION Radiation Therapy
- DRUG Temozolomide
- DRUG Ruxolitinib
Study Locations (1)
Florida
- Miami Cancer Institute at Baptist Health, Inc. - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2025-12-03 |
| Est. Completion | 2030-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06991101
The ClinicalTrials.gov registry entry for NCT06991101 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 190 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target (76% higher). The listed sponsor is Baptist Health South Florida, which has 40 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Glioblastoma appearing as the primary indexed condition, and to 3 interventions - of which Radiation Therapy is the first listed.
NCT06991101 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06991101 about?
NCT06991101 is a clinical study titled "Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma". The purpose of this research is to test the safety and effectiveness of the investigational drug ruxolitinib when it is combined with standard of care treatment (radiation therapy and temozolomide) for the treatment of newly diagnosed glioblastoma. Half the people in the study will be assigned to ta...
What is the current status of trial NCT06991101?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 190 participants. The study started on 2025-12-03. Estimated completion is 2030-12.
What conditions does trial NCT06991101 study?
This clinical trial studies the following conditions: Glioblastoma, Glioblastoma Multiforme, Brain Cancer, Glioblastoma Multiforme of Brain, Glioblastoma Multiforme, Adult.
What interventions are being tested in trial NCT06991101?
The interventions under investigation include: Radiation Therapy (RADIATION), Temozolomide (DRUG), Ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT06991101?
This trial is sponsored by Baptist Health South Florida, which has 40 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06991101 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
Surgical Pembro +/- Olaparib w TMZ for rGBM
RECRUITING · Phase 2
-
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RECRUITING · Phase 2
-
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.